What To Expect As Roivant Sciences Ltd (NASDAQ: ROIV) Delivers An 9.46% Gain In 6 Months


During the last session, Roivant Sciences Ltd (NASDAQ:ROIV)’s traded shares were 21.76 million, with the beta value of the company hitting 1.33. At the end of the trading day, the stock’s price was $11.51, reflecting an intraday gain of 5.40% or $0.59. The 52-week high for the ROIV share is $13.24, that puts it down -15.03 from that peak though still a striking 39.44% gain since the share price plummeted to a 52-week low of $6.97. The company’s market capitalization is $9.28B, and the average intraday trading volume over the past 10 days was 18.27 million shares, and the average trade volume was 7.05 million shares over the past three months.

Roivant Sciences Ltd (NASDAQ:ROIV) trade information

Roivant Sciences Ltd (ROIV) registered a 5.40% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 5.40% in intraday trading to $11.51, hitting a weekly high. The stock’s 5-day price performance is 14.19%, and it has moved by 0.26% in 30 days. Based on these gigs, the overall price performance for the year is 55.96%. The short interest in Roivant Sciences Ltd (NASDAQ:ROIV) is 31.57 million shares and it means that shorts have 6.07 day(s) to cover.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Roivant Sciences Ltd (ROIV) estimates and forecasts

Statistics show that Roivant Sciences Ltd has outperformed its competitors in share price, compared to the industry in which it operates. Roivant Sciences Ltd (ROIV) shares have gone up 9.46% during the last six months, with a year-to-date growth rate more than the industry average at 34.81% against 13.60. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -50.00% this quarter and then drop -10.50% in the quarter after that. In the rating firms’ projections, revenue will increase 136.80% compared to the previous financial year.

Revenue for the current quarter is expected to be $33.28 million as predicted by 9 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to $47.61 million by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $27.38 million and $25.07 million respectively. In this case, analysts expect current quarter sales to grow by 21.60% and then jump by 89.90% in the coming quarter.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 21.79%. While earnings are projected to return 559.45% in 2024.

ROIV Dividends

Roivant Sciences Ltd is due to release its next quarterly earnings on February 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Roivant Sciences Ltd (NASDAQ:ROIV)’s Major holders

Roivant Sciences Ltd insiders own 29.40% of total outstanding shares while institutional holders control 62.06%, with the float percentage being 87.90%. QVT Financial LP is the largest shareholder of the company, while 311 institutions own stock in it. As of Jun 29, 2023, the company held over 122.54 million shares (or 15.88% of all shares), a total value of $1.24 billion in shares.

The next largest institutional holding, with 83.03 million shares, is of SB Investment Advisers (UK) LTD’s that is approximately 10.76% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $836.96 million.

Also, the Mutual Funds coming in first place with the largest holdings of Roivant Sciences Ltd (ROIV) shares are Fidelity Growth Company Fund and Vanguard Specialized-Health Care Fund. Data provided on Aug 30, 2023 indicates that Fidelity Growth Company Fund owns about 10.3 million shares. This amounts to just over 1.33 percent of the company’s overall shares, with a $119.14 million market value. The same data shows that the other fund manager holds slightly less at 9.57 million, or about 1.24% of the stock, which is worth about $114.67 million.